Canadian Journal of Health Technologies
Pegzilarginase (Loargys)
Canada’s Drug Agency (CDA-AMC) recommends that Loargys be reimbursed by public drug plans for the treatment of hyperargininemia in adults and pediatric patients aged 2 years or older with arginase 1 deficiency (ARG1-D), in conjunction with dietary protein restriction, if certain conditions are met. The Canadian Drug Expert Committee (CDEC) determined that it is uncertain whether Loargys demonstrates acceptable clinical value compared with placebo plus individualized disease management in adults and pediatric patien …